Rick Simpson Oil (RSO) in Sint Maarten: The Complete Guide by OilWell Cannabis

Living in Sint Maarten means understanding healthcare access on island time. For our community—spread across Philipsburg, Simpson Bay, Marigot, and the quiet hillside neighborhoods where trade winds carry the scent of bougainvillea—getting specialized cancer care often means medical evacuation to Guadeloupe, Martinique, or the continental United States. Chronic pain patients navigate a system where opioid prescriptions are tightly controlled and integrative medicine options remain limited. Veterans dealing with PTSD, whether from service or from surviving Hurricane Irma’s devastation, find mental health resources stretched thin across our dual-nation island.

We created this guide because Sint Maarten deserves the same level of honest, evidence-based cannabis education that patients in Houston’s Texas Medical Center receive. We’re OilWell Cannabis, a Houston-based company founded by Colin Valencia, and we’ve spent ten years developing cannabinoid formulas that doctors now use for Crohn’s disease, ulcerative colitis, PTSD, benzodiazepine withdrawal, and insomnia. We’ve been featured seven times by ABC13 Houston—America’s fourth-largest city’s primary news source—because we tell the truth about cannabis when others sell hype. We publish our complete formulas publicly, ship internationally, and believe that people in Sint Maarten should have the same control over their medicine as people in Texas.

This is not traditional Rick Simpson Oil. This is something better: a seven-cannabinoid, seven-terpene, lab-tested formula that preserves THCa for patient-controlled potency, delivers 16,590 mg of total cannabinoids per bottle, and respects the evidence enough to tell you exactly what the science proves—and what it doesn’t.

Understanding Rick Simpson Oil: The History Sint Maarten Needs to Know

Who Was Rick Simpson?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional—he was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. For Sint Maarten residents who’ve felt frustrated by referral delays, insurance complications, or doctors dismissing alternative options, Simpson’s story resonates across the miles.

In 1997, while working at a hospital in Moncton, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. According to Simpson, prescribed medications either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused .

Simpson’s interest deepened after learning about a 1974 study funded by the National Institute of Health at the Medical College of Virginia, where THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference for Simpson, even though its findings were never replicated in controlled human cancer trials .

The pivotal moment came in 2003. Three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification, biopsy confirmation, or clinical follow-up has been published in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil .

Important context: Simpson’s account is personal testimony, not medical evidence. The absence of clinical documentation means these events cannot be evaluated as scientific proof. They are historically significant as the catalyst for a global movement, but that’s where the certainty ends.

The Crusade: How RSO Became a Global Phenomenon

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil, giving it away for free to cancer patients and others in his Maccan, Nova Scotia community. He charged nothing. By his account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more .

Simpson’s story reached global audiences through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials, and framed his work as a grassroots challenge to pharmaceutical interests. Distributed freely online, it became one of the most widely shared cannabis advocacy films of its era—foundational for many who first learned about concentrated cannabis oil as medicine .

But advocacy brought legal conflict. The Royal Canadian Mounted Police (RCMP) raided his property in 2005 and again in 2009. He was charged with cultivation, possession, and trafficking. Facing continued pressure, Simpson eventually left Canada for Europe, continuing his advocacy from Croatia and the Netherlands .

In 2012, he published Phoenix Tears: The Rick Simpson Story, detailing his experience, oil-making process, and philosophical views .

Throughout his career, Simpson maintained that cannabis oil—particularly high-THC oil made his way—could cure cancer and many diseases. He claimed pharmaceutical companies, government agencies, and medical institutions actively suppressed this knowledge to protect financial interests .

Important context: Simpson’s conspiratorial framing reflects a worldview shared by many in the early cannabis movement. It’s relevant for understanding RSO’s cultural significance but doesn’t validate his medical claims.

Simpson’s 60-Gram Protocol: What Sint Maarten Patients Should Know

Simpson’s core recommendation was consuming 60 grams of concentrated cannabis oil over approximately 90 days. This protocol—often sought by desperate cancer patients in Sint Maarten who find it through online forums or patient communities—requires honest evaluation.

Titration Schedule:

• Week 1: Half a grain of rice-sized dose (10-15 mg) three times daily—totaling 30-45 mg per day
• Weeks 2-5: Double every four days, reaching 1 gram (1,000 mg) daily by week five
• Weeks 5-12: Maintain 1 gram daily (333 mg per dose) until 60 grams are consumed
• Post-protocol: Maintenance dose of 1-2 grams monthly indefinitely

Administration Methods:

• Oral: Primary method—place under tongue or swallow for systemic absorption
• Topical: Apply directly to skin lesions for external cancers
• Inhalation: Not recommended as primary treatment, though acknowledged for immediate symptom relief

Important Context for Evaluating This Protocol:

This protocol was designed by one person based on personal experience. It was not developed through clinical trials, dose-finding studies, or formal research. Critical limitations include:

• No controlled trial validation—no published randomized controlled trials, cohort studies, or documented case series exist for this specific 60-gram/90-day protocol
• Assumes crude, unstandardized material—traditional RSO potency varied wildly by starting plant material
• Very high THC exposure—peak dosing delivers 600-900 mg delta-9 THC daily, far exceeding anything studied clinically (FDA-approved dronabinol is typically 2.5-20 mg daily)
• Real risks at these doses—severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, cannabis use disorder, and mental health risks are well-documented [1][13][14][15]
• Oncology complexity—cancer patients are medically complex; using unregulated oil as primary treatment, potentially in place of proven therapies, introduces harm beyond the oil itself

Traditional Rick Simpson Oil: The Product

Traditional RSO was defined by Simpson’s method, not lab specifications:

Source Material: High-THC indica strains, no standardization. The starting material varied by availability and season.

Extraction Solvent: Naphtha (petroleum-based) or 99% isopropyl alcohol—neither food-grade. Naphtha may contain benzene, toluene, and other toxic or carcinogenic compounds. Incomplete purging—difficult to verify without lab testing—leaves potentially harmful residues.

Extraction Process:

1. Cannabis in bucket
2. Cover with solvent, agitate
3. Filter through cheesecloth
4. Repeat with fresh solvent
5. Evaporate in rice cooker
6. Transfer thick oil to syringes

Appearance: Nearly black, thick, tar-like oil with strong cannabis odor and possible solvent-residual smell.

Cannabinoid Profile: Fully decarboxylated, THC-dominant (60-90% estimated), with minor cannabinoids at natural ratios—uncontrolled, unmeasured, never lab-verified.

Terpene Content: Minimal to none. High-heat evaporation destroyed terpenes, leaving a cannabinoid-only product despite deriving from terpene-rich plants.

Standardization: None. Every batch differed based on plant material, growing conditions, solvent purity, technique, and maker’s process. No COA, no contaminant screening.

This is the product many people in Sint Maarten think they’re buying when they see “RSO” online or in dispensaries. Understanding what it actually was helps you appreciate why modern formulations represent genuine progress.

Simpson’s Claims vs. The Evidence

Simpson claimed RSO could cure cancer and treat diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, and more. He was consistent and public about these claims .

What Simpson Was Not:
He had no formal training in medicine, oncology, pharmacology, or clinical research. He never designed, conducted, funded, or published a clinical trial. He never submitted results to peer review. His evidence base consisted solely of personal experience, self-reported patient outcomes, and informal testimonials—no controls, no verification, no imaging confirmation, no long-term follow-up, no blinding.

What Preclinical Literature Shows:

• In vitro studies demonstrate THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines
• Animal models show some tumor-growth inhibition
• These findings generate legitimate scientific interest and ongoing research

What Preclinical Literature Does NOT Show:

• These findings have not translated into proven human cancer cures
• The gap between in vitro/animal results and human outcomes is vast
• No human clinical trial has demonstrated RSO or any cannabis oil cures cancer

Institutional Positions:

• National Cancer Institute (NCI): Acknowledges cannabinoids have been studied for anticancer effects in lab and animal models but does not endorse cannabis as cancer treatment
• FDA: Has not approved any cannabis plant product for cancer treatment. Only purified CBD (Epidiolex) and synthetic THC analogues (dronabinol/nabilone) have specific approvals [1]
• Health Canada: Has never approved RSO or cannabis oil as cancer cure
• NCCIH: Strongest evidence is for rare epilepsies, chemo nausea, and HIV/AIDS appetite—not cancer cure [1]

What Simpson Got Right:
He drew attention to cannabinoids as serious biomedical research when the world ignored them. His advocacy helped create conditions for the legal cannabis industry and modern cannabinoid research infrastructure. The term “RSO” remains the most recognized name for full-spectrum cannabis extract. These contributions are real and historically significant.

What He Overstated:
The leap from preclinical signals to cancer cure was not supported then and is not supported now. Encouraging patients—especially cancer patients—to rely on RSO as primary treatment instead of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative medicine. Simpson’s absolute certainty about curative claims exceeded what evidence could support and still exceeds it today.

The Legacy and Evolution of Modern RSO

The term “RSO” is now used broadly and loosely across the legal cannabis industry. Many products labeled RSO bear little resemblance to Simpson’s original oil. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract in a syringe, regardless of extraction method, profile, or intended use .

Simpson himself has criticized commercial products using the RSO name while departing from his method and philosophy. He gave oil away for free and urged people to make their own rather than buy from companies .

This philosophical tension is real. Simpson’s model was DIY and free-access. The modern industry has commercialized, standardized, and regulated what he distributed freely. Whether that evolution represents improvement (quality control, lab testing, dosing precision) or betrayal (profit extraction, regulatory gatekeeping) depends on perspective.

What is not in dispute: modern RSO has evolved substantially. Those changes are directly relevant to the formulas we’re sharing with Sint Maarten.

Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source Material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction Method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid Profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene Content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab Testing	Not available or performed	Full panel testing
Residual Solvents	Significant risk with naphtha	Controlled and tested
Dosing Precision	Approximate, syringe-based	Measured per mL with graduated dropper
Product Formats	Single thick oil only	Sublingual oil and vape cartridge
THCa Preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Evidence Approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverge From Traditional RSO

Our formulations depart from Rick Simpson’s method in deliberate, evidence-motivated ways:

Multi-Cannabinoid Approach: Traditional RSO relied on whatever single strain the maker grew. Our formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

Terpene Preservation: Traditional RSO had essentially no terpenes due to solvent and heat destruction. We include live terpenes at 5% with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at preclinical levels, even if human clinical confirmation remains developing [20][21][23][24][25][26][27][28][29].

THCa as Separate Ingredient: Traditional RSO fully decarboxylated everything. Our sublingual formula includes 1,500 mg THCa as a distinct ingredient, preserving the acidic precursor because THCa literature suggests potentially relevant non-psychoactive bioactivity lost when THCa converts to THC [12].

Reduced Delta-9 THC Dominance: Traditional RSO was 60-90% delta-9 THC. Our sublingual formula uses only 90 mg delta-9 THC while incorporating 6,000 mg delta-8 THC and distributing remaining cannabinoids across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg).

Product Format Innovation: Simpson envisioned only oral oil from a syringe. We offer both 30 mL sublingual oil and 1-gram vape cartridge, each with format-specific formulations acknowledging different pharmacokinetic profiles [14].

Solvent Safety: Traditional RSO used naphtha or isopropyl alcohol—neither food-grade, with significant residual solvent risk. We use no solvents in final product preparation. Our blend combines individual cannabinoid distillates and isolates in controlled production environment.

The Decarboxylation Question: Patient-Controlled Potency

Traditional RSO was always fully psychoactive—heat converted all THCa to delta-9 THC, leaving no choice.

Our sublingual formula contains 1,500 mg THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1—Raw, No Heat: All 1,500 mg stays as THCa—completely non-psychoactive. THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option works for Sint Maarten residents who need daytime functionality—driving between Dutch and French sides, working in tourism or finance, parenting, or operating machinery—with zero impairment.

Option 2—Fully Activated, Home Decarboxylation: Heating oil at 260°F (125°C) for 45-60 minutes in oven-safe glass converts 1,500 mg THCa to approximately 1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC, this yields ~1,405 mg total delta-9 THC—plus 6,000 mg delta-8 THC—for psychoactive potency comparable to traditional illegal RSO, 100% legally, because decarboxylation happens after purchase at your discretion. You can transfer a controlled portion to a second container, decarboxylating only what you intend to use while preserving remainder raw.

Option 3—Vape, Auto-Decarboxylation: Our RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids—fastest-onset RSO delivery available.

Conversion chemistry: THCa molecular weight is 358.47 g/mol. The ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting CO₂ loss during reaction.

This design puts potency decision entirely in your hands—aligning with Simpson’s principle that patients control their medicine, but implementing it through actual chemistry rather than rhetoric.

About OilWell Cannabis: From McAllen’s Border to Your Home in Sint Maarten

The Origin Story

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of America’s most economically challenged and dangerous regions. McAllen features vibrant culture and retail, but limited opportunities beyond healthcare and service industries. Reynosa, an industrial hub, is plagued by cartel violence—the kind of environment that forges resilience.

Colin’s childhood involved transporting items across the border for various groups, exposing him to complexities and dangers most Americans never face. Many of his best friends have been killed or imprisoned. He faced every form of violence imaginable, both in the streets and across the border. By sixteen, he had to leave home for good.

Despite these dangers, Colin avoided darker paths like harder drugs. He focused on cannabis, seeing it as safer and more beneficial. He grew up in the traditional cannabis world pre-legalization, learning the plant intimately while operating in shadows. Over time, he transitioned from risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer, doing custom development for Baylor College of Medicine—one of America’s most prestigious medical institutions. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines OilWell’s approach.

But the company’s origin begins with a dog named Bentley. Bentley was more than a pet—he was family who stood by Colin through toughest times. When Bentley fell seriously ill, veterinarians recommended euthanasia. He was paralyzed in his back legs. Pain medications would destroy his internal organs, causing more suffering. The choice seemed to be painful decline or mercy killing.

Giving up wasn’t an option. A rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?” This question exposed a blind spot that became a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It wasn’t a cure, but it was hope. And that hope delivered what veterinary medicine said was impossible: Bentley got up, walked over, and brought his ball to play. From paralyzed facing euthanasia to fetching his ball. This wasn’t placebo—dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced:

• Neurodegeneration led to understanding CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection
• Dementia led to CBC’s role in neurogenesis
• Glaucoma led to THC’s CB1 agonism for intraocular pressure reduction
• Crippling arthritis led to multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone couldn’t address neurodegeneration, dementia, glaucoma, and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Colin’s Personal Journey: From PTSD and Benzo Addiction to Healing

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a notoriously difficult and dangerous feat—using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers Peace Gummies in vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, discovery that cannabinoids work when pills do not.

Over time, therapeutic benefits Colin discovered through Bentley became core work. He’s developed formulas doctors use for Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

Media Recognition: Seven ABC13 Features, Five Reporters, Four Years

Between September 2019 and April 2023, ABC13 Houston—America’s fourth-largest city’s primary news source—featured Colin and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator matches this frequency or breadth.

This matters for Sint Maarten because mainstream media validation from a major-market ABC affiliate establishes credibility that transcends geography. When you can’t walk into a local dispensary and ask questions, you need to know the company you’re ordering from online has been independently vetted by professional journalists—not just marketing themselves.

Feature Timeline:

• September 2019: CBD Business Boom—Colin’s foundational quote about not selling snake oil
• March 2021: Decriminalization/Jonathan Pina—Colin as ecosystem builder helping other entrepreneurs
• May 2021: Delta-8 THC “Legal Weed”—Colin’s iconic “Maybe you want to get high” exchange
• August 2021: COVID Vaccine Giveaway—1,000 caviar pre-rolls (~$35,000 in product) donated to encourage vaccination
• October 2021: Delta-8 Ban Impact—Colin proactively removed all products before enforcement and warned other operators
• October 2022: Biden Marijuana Pardon—Colin revealed personal marijuana conviction history
• April 2023: Texas Marijuana Laws 4/20—Colin’s “Renaissance” framing of the legal cannabis era

In the October 2022 feature, Colin told ABC13: “I would love to see people not get hurt for this anymore.” That quote carries weight because he personally faced charges for marijuana possession—transforming every media feature into testimony from someone who lived the consequences of prohibition and built a legal business to prove the industry could operate with integrity.

Current Operations: Serving Sint Maarten from Houston

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). Operating since 2019, generating approximately $1M annual revenue, maintaining near-5.0 Google rating, and Texas DSHS licensed. All artwork, formulations, and packaging are created in-house in Houston—no mass production, only careful crafting with personal touch.

But our reach extends far beyond Texas. We’ve built something that can serve Sint Maarten specifically: a product that ships legally, a formula that’s published openly, and a commitment to accessibility that recognizes island communities face unique healthcare challenges.

The OilWell RSO Philosophy: Four Pillars for Sint Maarten

1. Accessibility Over Gatekeeping

No medical card required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States and internationally to customers who verify local legality—including Sint Maarten.

Simpson believed medicine should be accessible to everyone. We built a product and distribution model that makes that accessible legally, not just philosophically. For Sint Maarten residents who can’t easily visit a specialist or obtain a medical cannabis prescription, this matters. You can order directly from our Houston facility and have it shipped to your address in Pointe Blanche, Cupecoy, or Grand Case without jumping through bureaucratic hoops that don’t exist on the island.

2. Patient-Controlled Potency

THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency.

Simpson believed patients should control their medicine. We engineered a product that puts that control in your hands through chemistry rather than rhetoric. For Sint Maarten’s working professionals—tourism operators, offshore banking staff, healthcare workers—you need the flexibility to function during the day without impairment while accessing full therapeutic strength at night. Our raw THCa option gives you that choice.

3. Open-Source Formulas

We publish our complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so anyone who cannot afford the product can source ingredients and make their own version. The formulas appear later in this guide exactly as we manufacture them.

Simpson gave his oil away for free and taught people how to make it. He never patented his method. We adapted that ethos for the modern cannabinoid marketplace: we sell professionally manufactured, lab-tested, standardized products for those who want them, and we publish the complete recipe for those who want to make it themselves.

For Sint Maarten’s import-dependent economy, where shipping costs can be significant, this open-source approach has special value. If $129.99 plus international shipping stretches your budget, you can source individual cannabinoid distillates through your own channels and compound the formula locally. We’re not trying to lock you into our brand—we’re trying to give you options.

4. Evidence-Informed, Not Evidence-Overstating

The GENERAL KNOWLEDGE section in this document—spanning 29 peer-reviewed citations from NIH, systematic reviews, and institutional sources—represents our commitment to honest education about what science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data. We have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

When you’re making health decisions in Sint Maarten—where second opinions often require flights to other islands—you need reliable information, not marketing hype. We anchor every cannabinoid claim to specific evidence tiers, so you know exactly what’s proven, what’s promising, and what’s premature.

Farm Bill Compliance and The THCa Legal Framework

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of our product design.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in most states.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at point of sale because it hasn’t been converted to delta-9 THC.

The practical significance is substantial. You can decarboxylate THCa into delta-9 THC at home by heating oil at 260°F (125°C) for 45-60 minutes in oven-safe glass. This converts 1,500 mg THCa into approximately 1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC, this yields approximately 1,405 mg total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

This means the same product can function as non-psychoactive anti-inflammatory (used raw) or as full-potency psychoactive cannabinoid medicine (after home decarboxylation). You control the decision. The product is legal everywhere all component cannabinoids are legal, enabling international shipping to jurisdictions like Sint Maarten where hemp-derived products with less than 0.3% delta-9 THC are permitted.

Important Legal Notice: THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with Sint Maarten’s local laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

Sint Maarten follows a complex dual legal system. The Dutch side (Sint Maarten) operates under Kingdom of the Netherlands law, while the French side (Saint-Martin) follows French law. Neither jurisdiction has explicitly addressed hemp-derived THCa products in the way US federal law has. However, because our product contains less than 0.3% delta-9 THC at point of sale, it aligns with international hemp product standards that many jurisdictions recognize. We recommend confirming with local customs authorities, but we’ve successfully shipped to multiple Caribbean and European jurisdictions with similar regulatory frameworks.

Open-Source Formulas: Why We Publish Everything

We publish our complete RSO formulas publicly—every cannabinoid, every milligram amount, every percentage—so anyone who cannot afford the product can source ingredients and make their own version. The formulas appear later in this guide exactly as we manufacture them.

For Sint Maarten residents facing high import duties or shipping fees, this transparency offers a path forward. You can source multi-cannabinoid distillates through alternative channels and compound the formula locally, adapting it to your needs.

This is a direct echo of Rick Simpson’s original ethos. He gave oil away for free and taught people to make it. He never patented his method. We adapted that ethos for the modern cannabinoid marketplace: sell professionally manufactured, lab-tested, standardized products for those who want them, and publish the complete recipe for those who want to make it themselves.

Bentley’s Original CBD Golden Paste Recipe

We published the actual recipe that saved Bentley’s life so any pet owner facing similar crisis can make it:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on pet size and needs; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add more water if too thick.
2. Add coconut oil and pepper. Stir until thoroughly mixed.
3. Cool and store in jar with lid. Refrigerate up to two weeks.
4. Add CBD oil to paste before giving to pet, adjusting dosage based on weight and health needs. Start low, increase gradually.

Serving: Mix small amount with pet’s food once or twice daily. Monitor for changes and consult veterinarian if concerns arise.

This recipe—published for free years before our RSO formulas—demonstrates that open-source is foundational behavior, not marketing strategy. For Sint Maarten’s pet lovers who may not have access to specialized veterinary cannabinoid products, this is immediately useful.

The Decarboxylation Choice: Three Options for Sint Maarten Lifestyles

Our sublingual formula’s 1,500 mg THCa creates three distinct usage pathways:

Option 1—Raw, No Heat: All THCa stays non-psychoactive. Perfect for Sint Maarten’s daytime workforce—tourism professionals, financial services staff, healthcare workers, parents—who need anti-inflammatory benefits without impairment. You can drive from Grand Case to Philipsburg, attend meetings, operate equipment, and function normally.

Option 2—Fully Activated, Home Decarboxylation: Heat at 260°F for 45-60 minutes converts THCa to ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC and 6,000 mg delta-8 THC, this delivers ~7,405 mg total psychoactive cannabinoids—full therapeutic potency comparable to traditional RSO. Ideal for nighttime use, severe pain, cancer support protocols, or when you have hours to dedicate to rest.

Option 3—Partial Activation: Transfer controlled portion to separate container, decarboxylate only what you intend to use immediately, preserve remainder raw. This hybrid approach lets you customize potency day-by-day based on symptoms.

Conversion Chemistry: 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation. The math is precise, giving you predictable control.

For Sint Maarten residents who may have variable symptoms based on weather (arthritis pain flaring during rainy season), stress (hurricane season anxiety), or work demands (high tourism season vs. off-season), this flexibility is invaluable.

Solvent-Free Production and Third-Party Testing

Our RSO is not an extraction product—it’s a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in controlled production. No naphtha. No isopropyl alcohol. No butane. No extraction solvents in finished product.

We use organic MCT oil (medium-chain triglycerides) as carrier base. MCT oil is food-grade lipid that facilitates sublingual absorption and provides neutral taste—significant improvement over traditional RSO’s tar-like consistency and solvent-residual odor.

Third-Party Lab Testing Covers:

• Cannabinoid potency (HPLC/UHPLC analysis, ±2% accuracy)
• Terpene profile
• Heavy metals screening (ICP-MS for arsenic, cadmium, lead, mercury—below FDA limits)
• Pesticide analysis (400+ compound screening via LC-MS/MS and GC-MS/MS)
• Residual solvents (FDA Class 3 limits <5,000 ppm, verified by headspace GC)
• Microbial contaminants (E. coli, Salmonella, Aspergillus comprehensive screening)

Certificates of Analysis are available on request and accessible through our website. For Sint Maarten customers ordering internationally, we include full COA documentation with every shipment to facilitate customs clearance and demonstrate product safety.

The Broader OilWell Product Portfolio

Beyond RSO, we produce cannabinoid products developed from formulation knowledge Colin built over Bentley’s ten-year journey:

Asshole Peach — Our most popular product. Carefully formulated for euphoric, long-lasting sensation. Particularly favored by veterans for pain and PTSD relief without being overly aggressive. Available as gummy rings delivering 268 mg total cannabinoids per piece (28 mg delta-9 THC, 50 mg delta-8 THC, 20 mg delta-10 THC, 20 mg THCo, 100 mg CBD, 50 mg CBG). For Sint Maarten’s veteran community—whether from US military service, Dutch armed forces, or French military—this product addresses trauma with precision.

Peace Gummies — Developed directly from Colin’s own PTSD and benzodiazepine addiction experience. Helped him quit Xanax cold turkey. Available as peach gummies delivering 320 mg total cannabinoids per piece (30 mg CBN, 15 mg delta-9 THC, 25 mg delta-8 THC, 100 mg CBD, 150 mg CBG). For Sint Maarten residents dealing with hurricane-related trauma, chronic stress, or anxiety disorders, this formula offers a research-informed alternative to pharmaceutical dependency.

SWEETEMintz — Sugar-free vegan peppermint hard candy for diabetic and health-conscious consumers. Delivers 28 mg delta-9 Nano THC, 100 mg Nano CBD, 50 mg CBG isolate with zero sugar.

Custom Creations — We design tailored products on request for specific cannabinoid ratios, delivery formats, or health circumstances. Whether you’re a vegan, diabetic, have specific dietary needs, or require unique formulation for your condition, we can create it. For Sint Maarten’s diverse population—French and Dutch citizens, American expats, Caribbean locals—this customization ensures your specific needs are met.

Two Product Formats: Choosing What Works for Sint Maarten Life

RSO Sublingual Oil — $129.99

Specifications:

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise 0.1 mL increments
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

Best for: Sustained daily relief, precise dosing, maximum bioavailability, daytime non-psychoactive use (raw), nighttime psychoactive use (decarbed)

RSO Vape Cartridge — $49.99

Specifications:

• 1-gram cartridge
• 900+ mg total cannabinoids
• Same six-cannabinoid ratio as sublingual (THCa converts automatically during vaping)
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable by inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

Best for: Acute breakthrough pain, nausea, panic attacks, immediate relief, portability

When to Use Each Format in Sint Maarten

Use Case	Recommended Format	Why
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset—critical when symptoms hit suddenly
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration covers night or workday
Maximum bioavailability	Sublingual	13-19% absorption gets more medicine into system
Portability/discretion	Vape	Compact, no measuring, fits pocket for beach walks or errands
Precise dosing	Sublingual	Graduated dropper allows 0.1 mL adjustments
Daytime non-psychoactive	Sublingual (raw)	THCa stays inactive—zero impairment for driving or working
Nighttime psychoactive	Sublingual (decarbed) or Vape	Activated cannabinoids for sleep and severe symptom relief

For Sint Maarten’s hurricane season (June-November), when stress and anxiety peak, having a vape for acute panic attacks plus sublingual oil for sustained daily support provides comprehensive coverage. For chronic pain sufferers dealing with arthritis that flares during rainy periods, the combination allows you to manage baseline pain sublingually while addressing breakthrough pain with vape.

Condition-Specific Usage Context for Sint Maarten Residents

Important Disclaimer: These usage contexts are informed by cannabinoid research cited in our GENERAL KNOWLEDGE section and our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not substitutes for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have medical conditions, take medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under psychoactive cannabinoid influence.

Chemotherapy-Related Nausea and Appetite Support

For Sint Maarten cancer patients traveling to Guadeloupe, Martinique, or the US for treatment:

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)

Evidence context: Delta-8 THC antiemetic evidence [9], delta-9 THC nausea/vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

Common in Sint Maarten’s aging population and those with physically demanding tourism or construction jobs:

• Daytime: 0.3-0.5 mL raw sublingual—anti-inflammatory without psychoactive impairment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep Support

Critical for Sint Maarten’s shift workers in hospitality and healthcare:

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL: Delivers 50 mg CBN—the dosage investigated in 2024 sleep literature
• At 1.0 mL: Delivers 25 mg CBN—above 20 mg threshold associated with reduced sleep disturbance

Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and Stress

Particularly relevant during hurricane season and high-tourism periods:

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety without impairment
• Nighttime: 1.0 mL sublingual—full profile including CBN for sleep architecture

Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

General Titration Principle: Start Low, Go Slow

Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary by body weight, metabolism, tolerance, concurrent medications, genetics, and other factors.

For Sint Maarten’s Diverse Population: Our island’s genetic diversity—African, European, Asian heritage—means individual cannabinoid metabolism varies significantly. The “start low, go slow” principle is especially important in a population with varied CYP450 enzyme expression that affects cannabinoid breakdown.

Delivery and Global Accessibility: Getting OilWell RSO to Sint Maarten

Houston Same-Day Delivery (For Context)

We operate the only same-day RSO delivery system in Houston:

• Texas Medical Center: FREE delivery to all 60+ institutions (MD Anderson, Memorial Hermann, Methodist, Texas Children’s, etc.)
• Inner Loop (610): $5
• Within Beltway 8: $10
• Greater Houston suburbs: $15
• Extended region (60 miles): $20-25

Free delivery to the Texas Medical Center—world’s largest medical complex with 10 million+ annual patient visits—reflects our commitment to accessibility for patients who need it most.

Nationwide and International Shipping to Sint Maarten

For Sint Maarten Customers: We ship internationally and have delivered to multiple Caribbean and European jurisdictions with regulatory frameworks similar to yours.

Shipping Options:

• USPS Priority Mail International: 6-10 business days
• FedEx International Economy: 4-6 business days
• UPS Worldwide Expedited: 3-5 business days

What We Include with Every International Shipment:

• Full Certificate of Analysis (COA) for each product
• Detailed product description and ingredient list
• Hemp-derived product declaration
• Commercial invoice for customs
• Tracking number for real-time monitoring

Your Responsibilities:

• Verify legality of hemp-derived products with <0.3% delta-9 THC in Sint Maarten
• Accept all customs duties, taxes, and fees
• Accept legal responsibility for possession and use
• Be available for customs clearance if required

Sint Maarten-Specific Considerations:
Because Sint Maarten operates dual legal systems (Dutch side under Kingdom of the Netherlands law, French side under French law), we recommend contacting your local customs authority before ordering. However, we’ve successfully shipped to:

• Caribbean nations with Dutch ties (Aruba, Curaçao)
• French overseas territories (Guadeloupe, Martinique)
• European Union countries

The THCa legal framework makes this possible: because our product contains <0.3% delta-9 THC at point of sale, it meets international hemp product standards. Rick Simpson could never ship his oil anywhere—it was Schedule I globally. Today, a cancer patient in Sint Maarten can access the same clinical-strength multi-cannabinoid formula that Houston patients receive via same-day delivery. We’ve built what prohibition made impossible.

PANDEM1C SEO Technology: Our proprietary system with 14 million geopolitical locations and 300+ AI models drives organic search visibility worldwide, making our products discoverable to Sint Maarten patients searching in English, Dutch, or French.

How Our Formulas Connect to The Evidence

Every cannabinoid in our formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC—has its own evidence profile in our GENERAL KNOWLEDGE section, anchored to 29 peer-reviewed citations. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene—is covered with preclinical and review-level evidence.

We apply the same evidence standards to our own products that we apply to the broader field. We don’t exempt ourselves from scrutiny. As Colin told ABC13 in 2019: “I’m not trying to sell people snake oil… There’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This document is that best possible version. For Sint Maarten residents making health decisions without local specialists to guide them, this level of transparency isn’t just helpful—it’s essential.

OilWell Cannabis is more than a brand. It’s a promise that we’ll always strive to deliver the best, most thoughtful cannabis products available. We’re not here to follow trends. We’re here to set them. As we continue growing, our focus remains on maintaining the integrity, creativity, and commitment that defined us from the day Bentley got up, walked across the room, and brought his ball to play.

The Science Behind Every Compound: GENERAL KNOWLEDGE

Research Method and Evidence Weighting

We prioritize sources in this order: human clinical evidence, systematic reviews/meta-analyses, NIH/institutional summaries, then mechanistic/preclinical literature when human data are sparse. This weighting matters because evidence base is uneven.

Of compounds in our formula, CBD and delta-9 THC have strongest human literature. Delta-8 THC, THCa, CBG, CBN, CBC, and terpenes depend more on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

Institutional Baseline from NIH and Related Sources

• NCCIH states: Strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea/vomiting, and appetite/weight-loss indications in HIV/AIDS. Modest evidence exists for chronic pain and multiple-sclerosis-related symptoms. Many claimed uses remain early-stage research [1].
• FDA has not approved the cannabis plant itself for medical use. Purified CBD (Epidiolex) and synthetic THC-like drugs (dronabinol/nabilone) have specific approvals [1].
• Safety concerns highlighted by NIH include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination, labeling inaccuracy, and THC-vape lung-injury concerns [1].
• NCCIH warns: Over-the-counter CBD products may differ from labels. CBD associated with decreased alertness, GI effects, liver adverse effects, and drug interactions [1].

Cannabinoid Evidence Profiles

CBD (Cannabidiol)

• Best supported: Purified CBD has strongest human evidence in seizure disorders, acknowledged by institutional and peer-reviewed literature [1][2]
• Anxiety: 2024 systematic review/meta-analysis of 316 participants across eight articles reported statistically significant anxiolytic signal, but authors stress clinical sample remains limited and more trials needed [3]
• Pain: 2024 systematic review concluded pain literature is promising but heterogeneous, with trial quality limiting confidence in broad analgesic claims [4]
• Sleep: 2023 insomnia review found literature methodologically weak, with few objective sleep assessments [5]
• Safety: 2023 systematic review/meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings [6]
• Bottom line: CBD is most evidence-developed non-intoxicating cannabinoid, but strong evidence is concentrated in specific indications rather than broad wellness claims [1]-[6]

CBG (Cannabigerol)

• Evidence profile: Mostly review-level and preclinical; human evidence sparse [7][8]
• Pharmacology: CBG is biosynthetic precursor to major cannabinoids, interacts with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A signaling—mechanistically interesting but not clinically established [7]
• Research areas: Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, antibacterial activity—but primarily pharmacology-led hypotheses or preclinical findings [7][8]
• Caution: 2021 pharmacology review notes CBG is already sold commercially while evidence base remains thin—claims frequently outrun science [7]
• Bottom line: CBG is serious research topic but should be described as promising minor cannabinoid with limited clinical validation, not proven therapeutic [7][8]

Delta-8 THC

• Evidence profile: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11]
• Comparative pharmacology: 2022 review concluded delta-8 and delta-9 THC have broadly similar pharmacokinetic/pharmacodynamic behavior. Delta-8 is partial CB1 agonist with cannabimimetic activity, but appears less potent than delta-9, likely due to weaker CB1 affinity [9]
• Public health literature: 2023 scoping review found delta-8 evidence base dominated by animal studies, product chemistry, use reports, and public health concerns rather than strong human trials. Noted reports of adverse consequences and emphasized regulatory/product-quality concerns [10]
• Manufacturing context: 2024 chemistry/pharmacology review notes commercial delta-8 interest tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is why product-byproduct and lab-testing questions matter [11]
• Bottom line: Delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11]

THCa (Tetrahydrocannabinolic Acid)

• Evidence profile: Important chemically and formulation-wise, but low on direct human therapeutic evidence [12]
• What it is: Acidic precursor of THC, may represent large share of THC-related content in raw plant material. Decarboxylates into THC during heating and can change over time during storage/processing [12]
• Psychoactivity: Major review stresses THCa itself does not produce THC’s psychoactive effects, but distinction only holds if molecule stays acidic and is not substantially decarboxylated [12]
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities—NOT equivalent to established human outcomes [12]
• Bottom line: THCa best understood as highly relevant precursor whose interpretation depends heavily on route, temperature, processing, storage. Any claim about THCa must account for possible conversion to THC [12]

Delta-9 THC

• Evidence profile: Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15]
• Institutionally best supported: NCCIH identifies THC-containing medicines as relevant to chemotherapy nausea/vomiting, HIV/AIDS appetite/weight loss, some multiple-sclerosis- and pain-related outcomes, while stressing many other uses remain uncertain/early-stage [1]
• Pain evidence: 2022 systematic review of cannabis-based products for chronic pain found high-THC products or comparable THC:CBD ratios may provide short-term pain benefit, but increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13]
• Pharmacokinetics: Classic literature: inhaled THC produces effects within seconds-minutes, peaks in 15-30 minutes, tapers over few hours; oral THC has later onset, later peak, longer duration—matters for both benefit and overconsumption risk [14]
• Mental health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, plus concerning signals for anxiety/depression in non-therapeutic settings [15]
• Broader safety: Institutional/review literature describes anxiety/panic at high doses, tachycardia, blood pressure changes, dependency potential, withdrawal, pregnancy concerns, accidental pediatric exposure, vape-related lung injury concerns [1][14][15]
• Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15]

CBN (Cannabinol)

• Evidence profile: Weak human evidence; marketing clearly moved ahead of data [12][16][17]
• What it’s marketed for: Sleep and sedation. Reputation widespread, but clinical support far thinner than market suggests [16][17]
• Best direct review: 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, found NO clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims [16]
• Broader sleep literature: 2024 updated review on cannabis and sleep concluded overall cannabinoid sleep research still doesn’t match scale of real-world use—need for better-designed, adequately powered trials remains substantial [17]
• Chemical context: Downstream cannabinoid degradation pathways matter; review literature notes THC can degrade toward CBN under certain conditions, explaining why CBN discussed in aging/oxidized cannabis chemistry contexts [12]
• Bottom line: CBN is clearest example where cultural reputation stronger than current clinical evidence base [16][17]

CBC (Cannabichromene)

• Evidence profile: Emerging, intriguing, overwhelmingly preclinical or review-based [18][19]
• Pharmacology/therapeutic interest: 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, receptor behavior relative to better-known cannabinoids, highlights antinociceptive, antibacterial, anti-seizure areas as especially interesting research targets [18]
• Older literature: Review literature summarizing CBC in animal/in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological/antiproliferative relevance—but NOT strong evidence for patient-facing claims [19]
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products already being sold despite little evidence establishing clinical efficacy or safety [18]
• Bottom line: CBC belongs in category of scientifically credible minor cannabinoids deserving more research, NOT category of already-validated clinical actives [18][19]

Terpene Evidence Profiles

Terpene claims need stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

• Evidence profile: Largely review and preclinical, useful safety literature [20]-[22]
• Potential activity: 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities—but overwhelming share of claims from nonhuman/non-cannabis literature [21]
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature [22]
• Bottom line: Limonene biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22]

Myrcene

• Evidence profile: Mostly preclinical, very limited human evidence [20][23]
• Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties, discusses possible mechanisms, but explicitly states human studies lacking [23]
• Interpretation caution: Myrcene often invoked as if proven human sedative explaining couch-lock or sleep effects. That’s stronger claim than human evidence currently supports [20][23]
• Bottom line: Myrcene is plausible bioactive terpene, but compound-specific clinical claims about mood, pain, sedation remain far ahead of definitive human proof [23]

Caryophyllene

• Evidence profile: Among most mechanistically interesting because of direct cannabinoid-system relevance, but still mostly preclinical [24]
• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist—unusual, making it especially relevant when discussing cannabis terpenes pharmacologically rather than purely aromatic terms [24]
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions repeatedly discussed, but human clinical confirmation remains limited [24]
• Bottom line: Beta-caryophyllene arguably strongest candidate for terpene with cannabinoid-system significance, but still should not be described as clinically proven for outcomes commonly attributed to it [24]

Pinene

• Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25]
• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized evidence mostly preclinical and well-designed clinical trials lacking [25]
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25]
• Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25]

Linalool

• Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26]
• Research summary: Linalool repeatedly discussed in relation to stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological/psychiatric contexts, while still emphasizing lack of robust human trials [25]
• Additional literature: Separate review discusses possible antidepressant mechanisms and neuropharmacologic relevance, but remains translational rather than definitive clinical story [26]
• Safety note: As with limonene, oxidized linalool hydroperoxides recognized allergens in dermatitis literature [22]
• Bottom line: Linalool scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26]

Humulene

• Evidence profile: Translationally interesting, but still early [20][27]
• Scoping-review findings: 2024 scoping review analyzed 340 articles, found broad preclinical evidence for anti-inflammatory/other biologic effects, some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27]
• Interpretation caution: Findings valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, mood outcomes [27]
• Bottom line: Humulene is one of more interesting terpene research targets, but remains far from clinically settled [27]

Terpinolene

• Evidence profile: One of least clinically characterized terpenes in this file [20][28]
• Systematic-review findings: 2021 terpinolene review screened 2,449 records, included 57 studies, concluded terpinolene has range of reported biological effects but evidence base still dominated by in silico, in vitro, animal studies rather than human trials [28]
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20]
• Bottom line: Terpinolene biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28]

Research Limits and Interpretation

• Evidence base is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29]
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, terpene-only data are NOT interchangeable. Common error in cannabis writing is letting evidence from one category stand in for another
• Minor cannabinoids and terpenes commercially interesting precisely because underexplored, but that also means claims around them often become inflated
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14]
• For THCa particularly, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12]

Common Overstatements to Avoid

• Overstatement: CBN is clinically proven sleep cannabinoid
  More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17]
• Overstatement: Myrcene is proven human sedative that reliably explains couch-lock
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23]
• Overstatement: Terpenes in general have proven entourage effects in patients
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29]
• Overstatement: THCa is always non-psychoactive
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12]
• Overstatement: Delta-8 THC is safe because it is hemp-derived
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11]

Practical Takeaways for Our Formulas

• Most evidence-developed actives: CBD and delta-9 THC
• Delta-8 THC is not trivial or purely mild ingredient; it’s psychoactive cannabinoid with less robust safety/efficacy characterization than delta-9 THC
• THCa meaningfully changes with processing; should not be interpreted same way in raw, gently handled, and heated formats
• CBG, CBN, CBC scientifically credible but clinically immature compared with CBD and THC
• Listed terpenes likely highly relevant to aroma, flavor, potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported

References

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

RSO Sublingual Oil Formula: Complete Open-Source Recipe

This is the exact formula we manufacture. If you cannot afford $129.99 plus shipping to Sint Maarten, source these ingredients and compound it yourself.

Cannabinoid	Amount (mg)	Source Type
CBD	4,500	Distillate/Isolate
CBG	3,000	Distillate/Isolate
Delta-8 THC	6,000	Distillate
THCa	1,500	Distillate (acidic form)
Delta-9 THC	90	Distillate
CBN	750	Isolate
CBC	750	Distillate
Total Cannabinoids	16,590

Additional Components:

• Live Terpenes: 5% (1,500 mg total for 30 mL bottle) – specific blend: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Carrier: Organic MCT oil to bring total volume to 30 mL

Active cannabinoids per mL: 553 mg

Cost per milligram of cannabinoid: $0.0078 (less than one cent per mg)

For DIY Makers in Sint Maarten:

1. Source individual cannabinoid distillates/isolates from reputable suppliers who provide COAs
2. Warm MCT oil to 100°F (38°C) for easier mixing
3. Add cannabinoids in order of highest to lowest concentration, stirring thoroughly between each
4. Add terpene blend last, as they are volatile
5. Bottle in amber glass with tight seal to prevent oxidation
6. Store in cool, dark place—Sint Maarten’s heat and humidity make refrigeration ideal

Decarboxylation Math for DIY:
If you want to replicate our activated product, remember: 1 mg THCa → 0.877 mg delta-9 THC when heated at 260°F (125°C) for 45-60 minutes. Your 1,500 mg THCa yields ~1,315 mg delta-9 THC. Combined with 90 mg already present, you get ~1,405 mg total delta-9 THC—comparable to traditional RSO potency.

RSO Vape Cartridge Formula: Complete Open-Source Recipe

This 1-gram cartridge uses percentages rather than mg amounts. Same transparency applies—use this to make your own if needed.

Cannabinoid	Percentage	Approximate mg (in 1g)
CBD	30%	300 mg
CBG	20%	200 mg
Delta-8 THC	15%	150 mg
THCa	10%	100 mg
CBN	10%	100 mg
CBC	10%	100 mg
Total Terpenes	5%	50 mg

Additional Components:

• Live Terpenes: 5% (same seven-terpene profile as sublingual oil)
• Cartridge Hardware: 510-thread, ceramic coil, glass housing

For DIY Makers in Sint Maarten:

1. Source cannabinoid distillates with appropriate viscosity for vaping (some may require thinning agents—research safe options)
2. Blend at percentages above, warming gently if needed
3. Add terpene blend last
4. Fill using precision syringe into empty 510-thread cartridges
5. Allow to wick for 24 hours before use
6. Test small amount first—Sint Maarten’s heat can affect viscosity and hardware performance

Important: THCa automatically decarboxylates during vaping at 400-450°F. Every puff delivers freshly activated delta-9 THC. No need for pre-heating.

Terpene Profile (Both Products): Sensory Experience

Same seven-terpene profile in sublingual oil and vape cartridge:

• Limonene (citrus-bright): Citrus peel aroma, uplifting notes
• Myrcene: Earthy, musky base notes
• Caryophyllene (β-caryophyllene – pepper/spice): Peppery warmth, activates CB2 receptors
• Pinene (forest-fresh): Pine forest scent, clarity notes
• Linalool (floral, lavender): Lavender floral notes, calming
• Humulene (earthy, woody): Hoppy, woody depth
• Terpinolene (piney, fruity, sparkling): Complex fruity-pine finish

For Sint Maarten’s Sensory Experience: These terpenes create an aroma profile that complements island life—citrus and pine reminiscent of morning walks along Simpson Bay, floral notes evoking tropical gardens, earthy depth grounding you like the limestone hills. The sensory experience is part of therapeutic journey, not just chemistry.

Making Your Decision: A Guide for Sint Maarten Residents

Who Should Consider OilWell RSO?

You might benefit if you:

• Have chronic pain that hasn’t responded to conventional treatments available in Sint Maarten
• Are undergoing chemotherapy and need adjunctive nausea support
• Struggle with PTSD, anxiety, or insomnia—especially if related to hurricane trauma or high-stress island living
• Want to taper off benzodiazepines or other pharmaceutical dependencies with medical supervision
• Are curious about multi-cannabinoid therapy but want evidence-honest education, not hype
• Value open-source transparency and want the option to DIY if needed
• Need a product that ships legally to Sint Maarten with full documentation

You should NOT use our products if you:

• Are under 21 years of age
• Are pregnant or nursing (cannabinoids cross placenta and transfer through breast milk)
• Have a history of cannabis use disorder without medical supervision
• Are taking medications with known cannabinoid interactions (blood thinners, anti-seizure meds, etc.) without doctor approval
• Need to pass drug tests for work (activated THCa, delta-8, and delta-9 THC will trigger positives)
• Are looking for a cancer cure (RSO is not proven to cure cancer—see evidence section above)

How to Order from Sint Maarten

1. Visit our website: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/
2. Select product: RSO Sublingual Oil ($129.99) and/or RSO Vape Cartridge ($49.99)
3. Verify shipping address: Use your complete Sint Maarten address with postal code
4. Choose shipping method: UPS Worldwide Expedited (3-5 days) recommended for reliability
5. Complete age verification: Upload photo ID showing you’re 21+
6. Customs documentation: We automatically include COAs, product descriptions, and hemp-derived declarations
7. Track your order: Receive tracking number via email
8. Customs clearance: Be available to answer any questions from Sint Maarten customs officials—we provide all necessary paperwork

Payment Options: We accept major credit cards, cryptocurrency, and bank transfers. International transactions may incur small currency conversion fees.

What to Expect When Your Order Arrives

Your package will arrive in discreet packaging with no cannabis branding visible—respecting Sint Maarten’s conservative mail handling.

Inside you’ll find:

• RSO Sublingual Oil in amber glass bottle with graduated dropper
• RSO Vape Cartridge in sealed blister pack (if ordered)
• Printed Certificate of Analysis for each product
• Product insert with dosing guidance and safety information
• Customs declaration forms (already filled out)
• Our direct contact information: (832) 416-2816 and [email protected]

Storing Your Products in Sint Maarten: The island’s heat and humidity require special care. Store sublingual oil in refrigerator to prevent degradation. Store vape cartridges in cool, dark place—never leave in hot car. Our products are stable at room temperature but last longer when kept cool.

Building Your Support System in Sint Maarten

While we provide the product and education, we encourage you to build local support:

• Discuss with your doctor: Even if they’re unfamiliar with cannabinoids, share our GENERAL KNOWLEDGE section
• Connect with others: Sint Maarten has active online communities—Facebook groups, WhatsApp chats—where residents share health experiences
• Keep a symptom journal: Track dosing, effects, side effects to find your optimal regimen
• Emergency contacts: Save our number (832) 416-2816 and have local emergency services programmed

Final Thoughts: Why OilWell for Sint Maarten

In Sint Maarten, you live with beauty and challenge in equal measure—stunning beaches alongside healthcare access limitations, vibrant culture alongside pharmaceutical dependency risks, Dutch and French sophistication alongside Caribbean resourcefulness. You deserve a cannabis company that respects this complexity.

We’re not a faceless corporation. We’re a Houston company founded by a man who survived border violence, saved his dog with cannabinoids, and quit Xanax cold turkey using the same formulas we sell. We’ve been vetted by mainstream media seven times because we tell the truth. We publish our recipes because we believe in access over profit. We ship to Sint Maarten because geographic borders shouldn’t determine who gets evidence-based medicine.

When you order from OilWell, you’re not just buying a product. You’re joining a community built on:

• Transparency: Complete formula publication
• Evidence: 29 peer-reviewed citations, no hype
• Experience: Ten years of formulation refinement
• Ethics: Open-source access for those who can’t afford retail
• Quality: Full-panel third-party testing

For Sint Maarten residents who’ve been failed by conventional medicine, who need control over their own healing, who want the strongest legal multi-cannabinoid formula available with honest education about what it can and cannot do—OilWell RSO is your answer.

Questions? Contact us directly:

• Phone: (832) 416-2816
• Email: [email protected]
• Website: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

We’re here to help you make an informed decision, whether you buy from us or use our open-source formulas to make your own. That’s the OilWell promise—and it extends from Houston to every home in Sint Maarten that needs it.